FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic H... (eatment continues. There was a 23-24% i...)

FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C

Date:3/11/2009

eatment continues. There was a 23-24% incidence overall for injection site reactions or inflammation.

Individual serious adverse reactions occurred at a frequency less than or equal to 1% and included suicide attempt, suicidal ideation, severe depression; psychosis, aggressive reaction, relapse of drug addiction/overdose; nerve palsy (facial, oculomotor); cardiomyopathy, myocardial infarction, angina, pericardial effusion, retinal ischemia, retinal artery or vein thrombosis, blindness, decreased visual acuity, optic neuritis, transient ischemic attack, supraventricular arrhythmias, loss of consciousness; neutropenia, infection (sepsis, pneumonia, abscess, cellulitis); emphysema, bronchiolitis obliterans, pleural effusion, gastroenteritis, pancreatitis, gout, hyperglycemia, hyperthyroidism and hypothyroidism, autoimmune thrombocytopenia with or without purpura, rheumatoid arthritis, interstitial nephritis, lupus-like syndrome, sarcoidosis, aggravated psoriasis, urticaria, injection site necrosis, vasculitis and phototoxicity.

Additional serious adverse events included hallucinations. bipolar disorder, mania, encephalopathy (usually elderly treated with higher doses of PEGINTRON), hypotension, tachycardia, retinopathy including macular edema, retinal hemorrhage, cotton wool spots, papilledema, ischemic and hemorrhagic cerebrovascular events, bone marrow toxicity (cytopenia and very rarely aplastic anemia), thyroiditis, dental and periodontal disorders, hemorrhagic/ischemic colitis, dyspnea, pulmonary infiltrates, pneumonia, interstitial pneumonitis, hepatic failure, increases in serum creatinine in patients with renal insufficiency, acute hypersensitivity (angioedema, bronchoconstriction, anaphylaxis and cutaneous eruptions) and hypertriglyceridemia.

During the course of therapy lasting up to 48 weeks in patients ages 3 through 17 years receiving PEGINTRON/REBETOL combination therapy, weight loss and growth inhib
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435

Post Your Comments:

(Date:12/16/2009)... PITTSBURGH, Dec. 16 Cohera Medical Inc. ... in a study of its lead surgical adhesive ... major milestone in the company,s progression of the ... clinical investigation is a prospective, open-label, randomized study ... effect on wound drainage and associated complications in ...

(Date:12/16/2009)... Wash., Dec. 16 Verathon®, maker ... to announce that portable bladder volume ultrasound ... CDC guidelines for the Prevention of Catheter-Associated ... CDC guidelines, introduced in early November 2009, ... to 1981. The guidelines are located ...

(Date:12/16/2009)... Dec. 16 Siemens Healthcare ... solutions to help ... meet deadlines defined within the HITECH provision ... (ARRA). Featuring zero-percent interest terms ... to defer up-front payments associated with their ...

Breaking Medicine Technology:First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2 First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3 New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 2 New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 3 New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 4 New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 5 Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2 Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3 Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4 North Carolina Should Increase Cigarette Tax by 50 Cents to Save Lives and Raise Revenue 51095 1 North Carolina Should Increase Cigarette Tax by 50 Cents to Save Lives and Raise Revenue 51095 2 North Carolina Should Increase Cigarette Tax by 50 Cents to Save Lives and Raise Revenue 51095 3 Genetic Breakthrough Spells Hope for Lung Fibrosis Patients 51092 1 Genetic Breakthrough Spells Hope for Lung Fibrosis Patients 51092 2 Intellikine Completes 2451 Million Financing 12939 1 Intellikine Completes 2451 Million Financing 12939 2

[0] First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive [0] New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound [0] Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use

... Sept. 3 Panacea Pharmaceuticals,Inc. today announced ... covering,antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), ... These antibodies,were developed in collaboration with the ... exclusive, worldwide rights to this patent,for development ...

... to Discuss Phase 3 Plans with FDA, ... today that it successfully completed two key clinical ... low-dose, once-weekly,contraceptive patch, which the company refers to ... safety and efficacy study successfully met its,primary endpoint ...

Other Medicine Technology:Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2 Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3 Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4 Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2 Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3 Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4

Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch

(Date:12/17/2009)... marketing techniques, life coaching company puts free i-phone & ... http://itunes.apple.com/us/app/attainment-life-management/id345691804?mt=8 . For the Free download. , ... ... -- Utah based Attainment Life Management & Coaching is ... everything in life simplified into one little hand held ...

(Date:12/16/2009)... -- Austin,s Custom Tops , a local business ... Gray and Hill Country Home Health, a slider-eating throwdown ... 9th. Fifty people showed up to cheer on the ... of sliders in support of the local charity, The ... casual bet over who could eat the most burgers ...

(Date:12/16/2009)... December 16, 2009 -- Every year in the ... and 57,000 patients die of the disease, making it ... adults, after lung cancer. , As researchers and clinicians ... -- simultaneously generating thousands of studies producing more and ... researcher of cancer and genetics at Case Western Reserve ...

(Date:12/16/2009)... Dec. 16 Allscripts (Nasdaq: MDRX ... financial results for the three and six months ... opens on Monday, January 11, 2010. Allscripts management ... discuss the company,s earnings and other information at ... ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, Allscripts ...

(Date:12/16/2009)... HealthSciences Institute will sponsor a ... teams and organizations who serve individuals at ... in employer, health plan, medical home and ... offer free, noncommercial webinars on topics, solutions ... management and care improvement. Each webinar will ...

Breaking Medicine News(10 mins):Health News:Attainment Life Management & Coaching has just Debuted its Free Application for I-Phone and I-Touch Users 2 Health News:Austin-Based Business Co-Sponsors Gastric Feat for Charity 2 Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 2 Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 3 Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2 Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3 Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4 Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2 Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3

[0] Attainment Life Management & Coaching has just Debuted its Free Application for I-Phone and I-Touch Users [0] Austin-Based Business Co-Sponsors Gastric Feat for Charity [1] New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer'[0] Allscripts to Announce Second Quarter Fiscal 2010 Results [1] New Learning Collaborative to Prepare Clinicians for Better Chronic Care

... ingredients are now utilized,in thousands of consumer ... ,tea think-tank, notes that non-beverage,consumer products containing ... a global basis. Tea and "herbal tea" ... being formulated into,thousands of consumer products including, ...

... Laborie Medical Technologies,today announced that the TETRA(TM)-NIRS ... with marketing efforts for this new and,exciting technology ... Drug Administration,(USFDA)., Laborie Medical Technologies is initiating ... (ISO-13485) so that,TETRA(TM) can be made available to ...

... of surgery a patient with kidney cancer receives depends ... tumor size, demographic characteristics, or general medical health. The ... not be receiving the most appropriate surgical care. The ... of CANCER, a peer-reviewed journal of the American Cancer ...

... by the Biotechnology and Biological Sciences Research Council ... Molecular Pharmacology identifying the structure of a receptor ... epilepsy and pre-menstrual tension. The same receptor has ... alcohol. , The University of Cambridge team, in ...

... Major Cities, PHILADELPHIA, March 9 Today Shire ... program for,people with ulcerative colitis (UC), a disease that ... events will feature four,expert presenters and will provide an ... with others who have UC., Experts at each ...

... bullied workers had more stress, less commitment and higher ... -- Persistent criticism, belittling comments, bullying and other forms ... than sexual harassment, according to a Canadian study. ... organizations may be more attuned to helping victims, who ...

Other Medicine News:Health News:Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products 2 Health News:Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products 3 Health News:Laborie Medical Technologies Receives FDA Pre-Market Clearance for TETRA(TM)- NIRS Accessory for the US Market 2 Health News:Kidney cancer surgery often determined by surgeons' practice style, not medical factors 2 Health News:Scientists determine structure of brain receptor implicated in epilepsy and PMT 2 Health News:Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis 2 Health News:Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis 3 Health News:Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis 4 Health News:Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis 5 Health News:Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis 6 Health News:Aggression on Job More Harmful Than Sexual Harassment 2

Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products Laborie Medical Technologies Receives FDA Pre-Market Clearance for TETRA(TM)- NIRS Accessory for the US Market Kidney cancer surgery often determined by surgeons' practice style, not medical factors Scientists determine structure of brain receptor implicated in epilepsy and PMT Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis Aggression on Job More Harmful Than Sexual Harassment

SofTec Genu is the first functional brace that provides full soft tissue control, enhances natural muscle movement, prevents atrophy, increases proprioception and controls A/P laxity....

McDavid® Patella Knee Support helps relieve the symptoms of chondromalacia patellar subluxation and patellar tendonitis. Features two medial and two lateral spring-steel stays. 3/16" thick neopre...

... Orthosis Custom-fitted static-progressive orthosis ... Goniometer version has calibrated ... metal contacts skin. Includes ... bag. One size fits ...

... BODI™ Dynamic Orthosis is the dynamic ... application over time is proven effective in ... half the time of other therapies. Can ... Orthosis.,Indications: For all joint stiffness and soft ...

Medicine Products:

SofTec Genu McDavid® Patella Knee Support Comfy™ Knee Orthosis BODI™ Dynamic Orthosis

FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic H...(eatment continues. There was a 23-24% i...),Health